Renaissance BioScience Corp., a global leader in yeast bioengineering based in Vancouver, Canada, has appointed Dr. James Tansey to its Board of Directors, the company announced July 30. Dr. Tansey brings extensive experience in life sciences, technology commercialization, fundraising and corporate governance, which will support Renaissance’s development and global commercialization of its biotechnology platforms for crop protection and future applications in animal and human health.
Dr. Tansey is a professor at the University of British Columbia’s Sauder School of Business and was previously a faculty member at Oxford University’s Saïd Business School. He is a member of the founding team at Gemina Labs, where he supports fundraising, business development and shareholder strategy. He also serves on the boards of dynaCERT Inc. and Vanadium Resources Ltd., and is a Senior Advisor to InBC, British Columbia’s $500 million strategic investment fund. His focus on “Impact Investing” and environmental protection aligns with Renaissance’s mission to address environmental challenges through innovative yeast-based solutions.
Maurice Boucher, Renaissance Co-Founder and Executive Chairman, said in a statement: “We are delighted to welcome Dr. Tansey to the Renaissance Board of Directors. James brings an outstanding combination of entrepreneurial, strategic and governance experience, together with a strong track record of helping innovative technology companies grow.” Boucher added, “James has consistently focused on ‘Impact Investing’ and environmental protection and sustainability throughout his exceptional career, which fits well with the positive environmental impact of Renaissance’s technology platforms. His expertise will be a valuable asset for Renaissance as we continue developing and globally commercializing our biotechnology platforms.”
Dr. Tansey commented on his appointment: “Renaissance has developed an impressive portfolio of innovative technologies with significant commercial potential across agriculture, industrial biotechnology and animal and human health. I look forward to working with the Board and management team to help the company execute on its growth strategy and create long-term value.”
Dr. John Husnik, Renaissance Co-Founder, Director and CSO, noted: “We are excited to welcome Dr. Tansey to our board. His experience building companies, securing investment, and helping innovative technologies move toward commercialization will complement our scientific expertise and support Renaissance as we continue developing and expanding our leading technology platforms.”
The appointment comes as Renaissance advances its yeast bioengineering platforms, which produce yeast-derived RNA and virus-like particles (VLPs) initially targeting crop protection. The company’s technology has potential to reduce reliance on chemical pesticides and address sustainability challenges in agriculture. With Dr. Tansey’s background in impact investing and environmental sustainability, his board role is expected to strengthen Renaissance’s strategic direction and investor relations. For more information about Renaissance BioScience Corp., visit www.renaissancebioscience.com.
